Subscribe To
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) — ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the U.S. Food and Drug Administration (FDA) […] The post ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for...
Read More
Content Topics
Therapeutics
Receives
Clearance
Investigational
Drug
Application
Onl1204
Ophthalmic
Solution
Forex
Posted: Feb 1 2023, 12:00
Author Name: forextv
Views: 102025